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Liver metastases through a glass less darkly
Achieving R0 resection margins is the best way to cure colorectal liver metastases but patterns of recurrence
within the liver suggest that some lesions are missed by pre-operative imaging or intraoperative ultrasound
(IOUSS). Peloso and colleagues in this edition of HPB, describe a pilot study using the autofluorescent
qualities of indocyanine green (ICG) to increase the sensitivity of intraoperative detection of occult liver
metastases. They took a cohort of 25 patients who had undergone pre-operative CT and administered a bolus
of ICG the day before liver resection.At laparotomy, they used a near infrared camera to look for ICG-related
fluorescence and detected a number of occult metastases that were not seen on either pre-operative CT or
IOUSS. This study is interesting as it reports an improvement of detection in lesions that might currently be
missed. There are a number of limitations not least that CT was the comparative mode of cross-sectional
imaging used in this study whereas many centres use magnetic resonance imaging and fluorodeoxyglucose
positron emission tomography as a routine part of the pre-operative work up for colorectal metastases. New
imaging innovations must be compared with current gold standards to gain credibility. ICG is excreted by
hepatocytes through the biliary system and can accumulate in the gall bladder and bile ducts. It would be
interesting to knowwhether this creates a strong signal around the gall bladder whichmight potentially mask
metastases in this area. ICG has potential as an adjunct to intraoperative imaging in liver surgery and it will
be interesting to see how this story unfolds.
Stephen J Wigmore
When is resection useful for malignant pancreatic neuroendocrine
tumours (PNET's)?
In this issue of HPB, Zerbi et al. report an Italian multi-institutional prospective observational study
consisting of 140 patients with malignant PNET’s. The primary outcome measure was progression free
survival at two years. The median follow up was 20.9 months. Overall 2yr progression free survival was
63.8%. Following multivariate analysis it was shown radical resection was independently associated with
improved progression free and overall survival and would seem the standard of care when technically
possible. Patients were collected over a three year period (2004–2007) and numbers lost to follow up were
small. Follow up imaging was limited to CT raising issues with regard to accuracy of staging. In addition,
given this was a non intervention observational study there was variation amongst the 24 centres with regard
to diagnostic imaging and subsequent adjuvant therapies. Despite these issues, several important observa-
tions can be made from this well constructed paper. Of the 140 patients, 88% had non-functioning tumours.
Therefore it is interesting to try and determine if palliative resection in patients with non functioning PNET’s
offers a survival (preferably overall) or quality of life advantage. Almost 16% of patients underwent a
palliative resection including pancreaticoduodenectomy or liver resection. It would appear many were
symptomatic (17 of 22 patients). Unfortunately no quality of life data are provided but there was no
difference in progression free survival between those who underwent palliative resection as compared to
those who did not undergo surgery. Thus, it would seem important that future studies look at quality of life
if palliative resections are to be pursued. The authors should be congratulated for initiating such a project
and it raises the question whether larger international registries can be created by HPB societies and their
members to help improve the care of patients with rare pathological entities.
Saxon Connor
Predicting survival in pancreatic cancer . . . but to what end?
At first clinical encounter, the McGill Brisbane Scoring System (MBSS) for pancreatic cancer (PAC) patients
is readily derived from the clinical assessment of smoking status, pain, jaundice and reported weight loss
beyond 10%. Add blood tests for carbohydrate antigen 19-9 (CA 19-9) and bilirubin, and you may have
important answers as how to proceed. But how will you really use such predictive data, and to what end?
Emanating from a Best Oral presentation at the IHPBA 2012 Congress in Paris, Dumitra et al. report how
well four clinical strategies predict 9-month survival in 133 patients diagnosed with PAC. Upon rigorous
statistical analysis (predictive values, likelihood ratios), the combined score of MBSS together with CA
19-9/bilirubin ratio emerged as the most predictive strategy followed by MBSS alone. In fact, MBSS was
predictive for survival in both resectable and non-resectable PAC patients, reportedly better than pre-
operative imaging or resectionmargin status.And so, with bedside clinical evaluation and blood tests, we can
predict which PAC patients are likely to die. Is this a conversation we will want to have with a given PAC
patient? One wonders. To what real ends will we use predictive modeling? Ideally to ends that align with the
least risk, most benefit and some hope. Examples might include stratified inclusion criteria for clinical trials,
sensibly avoiding surgery in someone just too sick, or being maximally aggressive in others.
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